Published in Am J Hematol on April 01, 2003
Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials. Am J Cardiol (2005) 3.05
Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol (2005) 2.59
Abnormal angiogenesis in diabetes mellitus. Med Res Rev (2003) 2.41
Statin therapy may be associated with lower mortality in patients with diastolic heart failure: a preliminary report. Circulation (2005) 1.97
IRAK1 serves as a novel regulator essential for lipopolysaccharide-induced interleukin-10 gene expression. J Biol Chem (2004) 1.65
The cardiovascular effects of erythropoietin. Cardiovasc Res (2003) 1.59
Aspirin resistance in cardiovascular disease: a review of prevalence, mechanisms, and clinical significance. Thromb Haemost (2002) 1.58
Matrix metalloproteinases: a review of their structure and role in acute coronary syndrome. Cardiovasc Res (2003) 1.52
The inhibitory effect of calumenin on the vitamin K-dependent gamma-carboxylation system. Characterization of the system in normal and warfarin-resistant rats. J Biol Chem (2004) 1.31
Growth hormone, insulin-like growth factor-1 and the aging cardiovascular system. Cardiovasc Res (2002) 1.30
Risk of bleeding complications with antiplatelet agents: meta-analysis of 338,191 patients enrolled in 50 randomized controlled trials. Am J Hematol (2004) 1.23
Engineering of a recombinant vitamin K-dependent gamma-carboxylation system with enhanced gamma-carboxyglutamic acid forming capacity: evidence for a functional CXXC redox center in the system. J Biol Chem (2005) 1.12
Enhanced platelet/endothelial activation in depressed patients with acute coronary syndromes: evidence from recent clinical trials. Blood Coagul Fibrinolysis (2003) 1.12
Angiotensin II type 1 receptor blockade prevents alcoholic cardiomyopathy. Circulation (2006) 1.10
Mast cell tryptase: a new biomarker in patients with stable coronary artery disease. Atherosclerosis (2005) 1.05
Regulator of G protein signaling 5 marks peripheral arterial smooth muscle cells and is downregulated in atherosclerotic plaque. J Vasc Surg (2004) 1.00
Identification of chemical inhibitors to human tissue transglutaminase by screening existing drug libraries. Chem Biol (2008) 0.96
Vascular origin of a soluble truncated form of the hepatocyte growth factor receptor (c-met). Circ Res (2002) 0.96
Relation of anemia to diastolic heart failure and the effect on outcome. Am J Cardiol (2004) 0.96
ABO blood types: influence on infarct size, procedural characteristics and prognosis. Thromb Res (2008) 0.95
Absence of interaction between atorvastatin or other statins and clopidogrel: results from the interaction study. Arch Intern Med (2004) 0.95
Myocardial infarction in thrombotic thrombocytopenic purpura: a single-center experience and literature review. Eur J Haematol (2008) 0.94
Beyond the platelet count: heparin antibodies as independent risk predictors. Am Heart J (2007) 0.94
Anti-platelet factor 4/heparin antibodies: an independent predictor of 30-day myocardial infarction after acute coronary ischemic syndromes. Circulation (2003) 0.93
Cocaine use is associated with an increased risk of stent thrombosis after percutaneous coronary intervention. Am Heart J (2007) 0.92
Aging and thrombosis. Semin Thromb Hemost (2002) 0.92
Frequency of aspirin resistance in patients with congestive heart failure treated with antecedent aspirin. Am J Cardiol (2002) 0.92
Vitamin K 2,3-epoxide reductase and the vitamin K-dependent gamma-carboxylation system. Thromb Res (2002) 0.91
Intrabody and intrakine strategies for molecular therapy. Mol Ther (2003) 0.91
Angiostatin selectively inhibits signaling by hepatocyte growth factor in endothelial and smooth muscle cells. Blood (2002) 0.88
Relationship between release of platelet/endothelial biomarkers and plasma levels of sertraline and N-desmethylsertraline in acute coronary syndrome patients receiving SSRI treatment for depression. Am J Psychiatry (2005) 0.88
Statins increase risk of hemorrhagic stroke by inhibition of the PAR-1 receptor. Cerebrovasc Dis (2007) 0.88
Transglutaminases: the missing link in nephrogenic systemic fibrosis. Am J Dermatopathol (2007) 0.87
Chronic kidney disease and dipstick proteinuria are risk factors for stent thrombosis in patients with myocardial infarction. Am Heart J (2009) 0.86
Nicotine upregulates the expression of P2Y12 on vascular cells and megakaryoblasts. J Thromb Thrombolysis (2006) 0.85
Final results of the ReoPro readministration registry. Am J Cardiol (2004) 0.85
Valsartan inhibits platelet activity at different doses in mild to moderate hypertensives: Valsartan Inhibits Platelets (VIP) trial. Am Heart J (2006) 0.84
Reduced inhibition by abciximab in platelets with the PlA2 polymorphism. Am Heart J (2002) 0.84
N-Glycosylation engineering of tobacco plants to produce asialoerythropoietin. Plant Cell Rep (2012) 0.84
Routine hematologic clinical tests as prognostic markers in patients with acute coronary syndromes. Am Heart J (2008) 0.84
Cytoprotective effect of recombinant human erythropoietin produced in transgenic tobacco plants. PLoS One (2013) 0.84
Low plasma levels of FGF-2 and PDGF-BB are associated with cardiovascular events in type II diabetes mellitus (diabetes heart study). Dis Markers (2007) 0.84
Bleeding risks of combination vs. single antiplatelet therapy: a meta-analysis of 18 randomized trials comprising 129,314 patients. Fundam Clin Pharmacol (2008) 0.84
CT findings in acute myocarditis: 2 cases. J Thorac Imaging (2007) 0.83
Noncompliance in cardiovascular clinical trials. Am Heart J (2005) 0.83
Platelet and endothelial activity in comorbid major depression and coronary artery disease patients treated with citalopram: the Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy Trial (CREATE) biomarker sub-study. J Thromb Thrombolysis (2008) 0.82
Arterial vimentin is a transglutaminase substrate: a link between vasomotor activity and remodeling? J Vasc Res (2007) 0.81
Effect of statins on platelet PAR-1 thrombin receptor in patients with the metabolic syndrome (from the PAR-1 inhibition by statins [PARIS] study). Am J Cardiol (2006) 0.81
Role of anti-PF4/heparin antibodies in recurrent thrombotic events after acute coronary syndromes. Semin Thromb Hemost (2004) 0.80
Intrabody-based strategies for inhibition of vascular endothelial growth factor receptor-2: effects on apoptosis, cell growth, and angiogenesis. FASEB J (2003) 0.80
Aspirin inhibits surface glycoprotein IIb/IIIa, P-selectin, CD63, and CD107a receptor expression on human platelets. Blood Coagul Fibrinolysis (2003) 0.80
Effect of loading with clopidogrel at the time of coronary stenting on platelet aggregation and glycoprotein IIb/IIIa expression and platelet-leukocyte aggregate formation. Am J Cardiol (2002) 0.80
Weekly doxorubicin increases coronary arteriolar wall and adventitial thickness. PLoS One (2013) 0.79
Zebrafish with antisense-knockdown of cardiac troponin C as a model of hereditary dilated cardiomyopathy. Circ J (2009) 0.79
Magnitude and time course of platelet inhibition with Aggrenox and Aspirin in patients after ischemic stroke: the AGgrenox versus Aspirin Therapy Evaluation (AGATE) trial. Eur J Pharmacol (2004) 0.79
Antibodies to platelet factor 4/heparin are associated with elevated endothelial cell activation markers in patients with acute coronary ischemic syndromes. J Thromb Thrombolysis (2004) 0.79
Consistent platelet inhibition during long-term maintenance-dose clopidogrel therapy among 359 compliant outpatients with documented vascular disease. Am Heart J (2007) 0.79
The Ultegra rapid platelet-function assay: comparison to standard platelet function assays in patients undergoing percutaneous coronary intervention with abciximab therapy. Am Heart J (2002) 0.78
Paradoxical rebound platelet activation after painkillers cessation: missing risk for vascular events? Am J Med (2006) 0.78
Derived fibrinogen compared with C-reactive protein and brain natriuretic peptide for predicting events after myocardial infarction and coronary stenting. Am Heart J (2008) 0.78
Differences in baseline characteristics and in-hospital outcomes in patients with or without prior stroke undergoing percutaneous coronary intervention. J Invasive Cardiol (2005) 0.78
Unfractionated heparin reduces the anti-platelet effects of abciximab but not eptifibatide during PCI. Clin Appl Thromb Hemost (2006) 0.78
Lack of uniform platelet activation in patients after ischemic stroke and choice of antiplatelet therapy. Thromb Res (2004) 0.78
Calcification after myocardial infarction is independent of amniotic fluid stem cell injection. Cardiovasc Pathol (2010) 0.77
Effects of roxifiban on platelet aggregation and major receptor expression in patients with coronary artery disease for the Roxifiban Oral Compound Kinetics Evaluation Trial-I (ROCKET-I Platelet Substudy). Am Heart J (2003) 0.77
Could stent design affect platelet activation? Results of the Platelet Activation in STenting (PAST) Study. J Invasive Cardiol (2002) 0.77
Bicuspid aortic valves in monozygotic twins. Echocardiography (2003) 0.77
Argatroban, a direct thrombin inhibitor for heparin-induced thrombocytopaenia: present and future perspectives. Expert Opin Pharmacother (2006) 0.76
No effect of an L-arginine-enriched medical food (HeartBars) on endothelial function and platelet aggregation in subjects with hypercholesterolemia. Am Heart J (2003) 0.76
Platelet activation in patients with congestive heart failure: do we have enough evidence to consider clopidogrel? Am Heart J (2003) 0.76
Preprocedural white blood cell count and major adverse cardiac events late after percutaneous coronary intervention in saphenous vein grafts. Am J Cardiol (2005) 0.76
Stroke prevention: optimizing the response to a common threat. JAMA (2004) 0.75
Telomerase-positive neutrophils: plaque "survivors" and restenosis. J Am Coll Cardiol (2008) 0.75
C-Terminally fused affinity Strep-tag II is removed by proteolysis from recombinant human erythropoietin expressed in transgenic tobacco plants. Plant Cell Rep (2014) 0.75
Letter by Sane regarding article, "New-onset heart failure due to heart muscle disease in childhood: a prospective study in the United kingdom and Ireland". Circulation (2008) 0.75
Link between ADAMTS-13 and troponin levels? Crit Care Med (2008) 0.75
Optimal TARGETs for cardiovascular safety and benefit in ESRD. Nephrol Dial Transplant (2008) 0.75
Relation of platelet activation and myocardial ischemia biomarkers dependent on type of chest pain (abrupt onset versus intermittent) in patients with angina pectoris or non-Q-wave acute myocardial infarction. Am J Cardiol (2002) 0.75
Does heart failure etiology, New York Heart Association class, or ejection fraction affect the ability of clopidogrel to inhibit heightened platelet activity? Blood Coagul Fibrinolysis (2007) 0.75
Safety of abciximab administration during PCI of patients with previous stroke. J Thromb Thrombolysis (2005) 0.75
Persistent erythema with niacin is not attributable to aspirin resistance. J Clin Lipidol (2011) 0.75
Magnitude and time course of platelet inhibition with extended release dipyridamole with or without aspirin in healthy Japanese volunteers. The AGgrenox versus Aspirin Therapy Evaluation (AGATE-Japan). Thromb Haemost (2008) 0.75
Interference of thrombin in immunological assays for hirudin specific antibodies. J Immunol Methods (2012) 0.75
PCI with and without abciximab after upstream eptifibatide use: outcomes in high-risk patients. J Invasive Cardiol (2006) 0.75
Effects of valsartan and valeryl 4-hydroxy valsartan on human platelets: a possible additional mechanism for clinical benefits. J Cardiovasc Pharmacol (2004) 0.75
Superior in-hospital and 30-day outcomes with abciximab versus eptifibatide: a contemporary analysis of 495 consecutive percutaneous coronary interventions. J Invasive Cardiol (2004) 0.75